Large Molecule Drug Substance CDMO Market To Reach $101.41 Billion By 2033

Large Molecule Drug Substance CDMO Market Growth & Trends

The global large molecule drug substance CDMO market size is estimated to reach USD 101.41 billion by 2033, registering a CAGR of 7.71% from 2025 to 2033, according to a new report by Grand View Research, Inc. Rising incidence of infectious diseases and high demand for novel therapeutics are the key factors driving the market.

Contract manufacturing is one of the major steps in large molecule production and accounts for a sizable portion of the large molecule drug substance market. The mode of manufacturing is an important factor to consider because it represents the sector's outsourcing and in-house activities. Companies are now choosing to outsource services due to high costs and delays in time. This has resulted in a greater proportion of large molecules being outsourced by the firms. A contract development and manufacturing organization (CDMO) is a company that provides a comprehensive range of services to the pharmaceutical industry from drug development to manufacturing. CDMOs provide critical services by incorporating third-party projects and offering their knowledge, development, and manufacturing capabilities.

Prior to the COVID-19 pandemic, large molecule drug investment was increasing as it offers a plethora of new treatment options. The valuation of biologics became clearer during the race to develop therapeutics and vaccines against the SARS-CoV-2 virus. The demand for both high-volume and high-quality CGMP drug substance and drug product manufacturing services has risen dramatically, particularly for CDMOs capable of providing a wide range of COVID vaccine technologies and, to a lesser extent, therapeutic monoclonal antibody products.

 Request a free sample copy or view report summary: Large Molecule Drug Substance CDMO Market Report

Large Molecule Drug Substance CDMO Market Report Highlights

• Based on product, the biologics segment led the market with the largest revenue share of 77.25% in 2024, attributed to the increasing adoption of biologics in treating complex diseases such as cancer, autoimmune disorders, and rare conditions.

• Based on service, the contract manufacturing segment dominated the market in 20224, driven by growing demand for cost efficiency, scalability, and regulatory compliance.

• Based on source, the mammalian segment is anticipated to grow at the fastest CAGR during the forecast period. This category will expand as more complex biologics, such as bi- and tri-specific antibodies, and antibody–drug conjugates are evolved

• Based on end-user, the biotech companies segment accounted for the largest share in 2024. Rising R&D investment by the firms for large molecules drives the market.

• Asia Pacific large molecule drug substance CDMO market held the largest revenue share of 37.90% in 2024, boosted by rapidly rising biologics pipelines, the appeal of lower cost, high-quality manufacturing.

Large Molecule Drug Substance CDMO Market Segmentation

Grand View Research has segmented the global large molecule drug substance CDMO market based on product, service, source, end-use, and region:

Large Molecule Drug Substance CDMO Product Outlook (Revenue, USD Million, 2021 - 2033)

• Biologics

• Biosimilar

Large Molecule Drug Substance CDMO Service Outlook (Revenue, USD Million, 2021 - 2033)

• Contract Manufacturing

  • Clinical

  • Commercial

• Contract Development

  • Cell Line Development

  • Process Development

Large Molecule Drug Substance CDMO Source Outlook (Revenue, USD Million, 2021 - 2033)

• Mammalian

• Microbial

• Others

Large Molecule Drug Substance CDMO End-use Outlook (Revenue, USD Million, 2021 - 2033)

• Biotech Companies

• CRO

• Others

Large Molecule Drug Substance CDMO Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • UAE

  • Saudi Arabia

  • Kuwait

  • Qatar

  • Oman

List of Key Players in the Large Molecule Drug Substance CDMO Market

• Eurofins Scientific

• WuXi Biologics

• Samsung Biologics

• Catalent, Inc.

• Rentschler Biopharma SE

• AGC Biologics

• Recipharm AB

• Siegfried Holding AG

• Boehringer Ingelheim

• FUJIFILM Diosynth Biotechnologies